1209646-17-2

Basic information

• Product Name: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid
• Synonyms: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid;5-(4-(tert-Butoxycarbonyl)
• CAS NO: 1209646-17-2
• Molecular Formula: C₁₄H₂₀N₄O₄
• Molecular Weight: 308.333
• EINECS: -0
• Mol File: 1209646-17-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid(1209646-17-2)
• EPA Substance Registry System: 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid(1209646-17-2)

Safety Data

• Hazardous Substances Data: 1209646-17-2(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid is used as a building block for the synthesis of other compounds due to its unique structure and functional groups. Its potential biological activity and versatility in chemical modifications make it valuable in the development of new pharmaceutical agents.
Used in Drug Development:
In the pharmaceutical industry, 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid is used as a precursor for the creation of novel drug candidates. Its ability to be modified and combined with other molecules allows for the exploration of its therapeutic potential in treating various diseases and conditions.
Used in Chemical Research:
5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid serves as a subject of study in chemical research, where its properties, reactivity, and potential applications are investigated. Understanding its behavior in different chemical environments can lead to the discovery of new reactions and synthetic pathways.
Used in Biochemical Studies:
In the field of biochemistry, 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid may be employed to study its interactions with biological molecules, such as enzymes, receptors, or other cellular components. This can provide insights into its potential biological activity and help in the design of more effective drugs.
Note: The specific applications and uses of 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylic acid would depend on further studies and experimentation to determine its exact properties and potential therapeutic effects.

Upstream product

• 876161-05-6 5-bromopyrazine-2-carboxylic acida 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 34604-60-9 5-hydroxypyrazinoic acid 
• 1215626-40-6 methyl 5-(4-(tert-butoxycarbonyl)piperazin-1-yl)pyrazine-2-carboxylate 
• 33332-25-1 methyl 5-chloropyrazine-2-carboxylate 

Downstream Products

• 1360552-50-6 5'-(3-{1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic Acid tert-butyl ester 
• 1360552-56-2 5'-(3-{(S)-1-[4-(5-amino-pyrazin-2-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic Acid tert-butyl Ester 
• 1360552-49-3 C₂₆H₃₁BrN₆O₃ 
• 1360552-55-1 C₂₆H₃₁BrN₆O₃ 
• 1361190-35-3 5'-(3-{1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-cyclobutyl}-[1,2,4]oxadiazol-5-yl)-2,3,5,6-tetrahydro-[1,2']bipyrazinyl-4-carboxylic acid tert-butyl ester 
• 1361189-31-2 5-(4-{1-[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-[1,2,4]oxadiazol-3-yl]-cyclobutyl}-phenyl)pyrazin-2-ylamine 
• 1361189-25-4 5-(4-{1-[5-(3,4,5,6-tetrahydro-2H-[1,2']bipyrazinyl-5'-yl)-[1,2,4]oxadiazol-3-yl]-cyclobutyl}-phenyl)pyridin-2-ylamine 
• 1361187-57-6 5-(4-{1-[5-(3,4,5,6-tetrahydro-2H-1,2'-bipyrazinyl-5'-yl)-1,2,4-oxadiazol-3-yl]-cyclobutyl}-phenyl)-pyrimidin-2-ylamine 

Relevant articles and documents

PIPERIDINYL AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE

The present invention relates to compounds of formula (I), wherein R1, R2, R3, R4 and R5 are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and co

Protein degradation targeting chimera for degrading androgen receptor

The invention relates to a novel difunctional molecule compound based on VHL ligand induction and application of the difunctional molecule compound in synthesis of the compounds and pharmaceutical compositions thereof. The compound is shown as a formula I. The compound can selectively induce AR protein degradation and can be used for treating cancers such as prostatic cancer and breast cancer.

PYRIMIDINE AND PYRAZINE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

SELECTIVE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compounds of formula (I) and (IA) and pharmaceutically acceptable salts thereof, wherein R1- R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, metho

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I) and pharmaceutically acceptable salt thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.